Subject : Potassium Competitive Acid Blockers: Clinician’s perspective in the management of acid peptic disorders
Proton pump inhibitors (PPIs) have demonstrated good efficacy with excellent safety profiles for indications across acid peptic disorders, with widespread availability and use in clinical practice. However, the potential for more rapidly acting, acid-stable, and/or increasingly potent antisecretory agents to mitigate some limitations of PPI medications has fostered the development and interest in novel potassium-competitive acid blockers (P-CABs).
The evolving P-CAB class currently includes fexuprazan, keverprazan, revaprazan, tegoprazan, and vonoprazan, with others under development (ie, linaprazan, zastaprazan). Of these, vonoprazan has been the most extensively studied and was initially approved in Japan in 2015 for the treatment of acid-related diseases (gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer, adjunct to Helicobacter pylori [HP] eradication), with subsequent expansion of approvals to other countries. Tegoprazan was approved in South Korea in 2019. In May 2022, the US Food and Drug Administration approved 2 vonoprazan-containing HP treatment regimens (vonoprazan plus amoxicillin and clarithromycin and vonoprazan plus amoxicillin and accepted filing of a New Drug Application for vonoprazan for the treatment of erosive esophagitis (EE)
Clinical perspective from Indian healthcare practitioners about P-CAB class can help other practicing HCPs in the management of acid peptic disorders.
If you agree to participate, you will be required to respond to questions of the enclosed questionnaire. We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate to share your clinical perspective on P-CAB class of drugs. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})